Medicines List

Select category
  • Description

    Capeda belongs to the group of medicines called “cytostatic agents”, which stop the growth of cancer cells. Capeda Tablets contain 150mg or 500mg capecitabine, which itself is not a cytostatic agent. Only after being absorbed by the body is it changed into an active anti-cancer agent (more in tumour tissue than in normal tissue).

    Indications

    Capeda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1 of SPC).

    Capeda is indicated for the treatment of metastatic colorectal cancer (see section 5.1 of SPC).

    Capeda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen (see section 5.1 of SPC).

    Capeda in combination with docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

    Subject to medical prescription

    Pharmaceutical form: 150 mg film-coated tablets x 60 tablets

    NHIF code:

    ICD:C50; C16; C18; C19; C20

    Pharmaceutical form: 500 mg film-coated tablets x 120 tablets

    NHIF code:

    ICD:C50; C16; C18; C19; C20

    АТС code: L01BC06

    capeda_500mg_3d
  • Description

    Hronileucem is a medicine containing an active substance called imatinib. This medicine works by inhibiting
    the growth of abnormal cells in the diseases listed below. These include some types of cancer.

    Indications

    Hronileucem is indicated for the treatment of

    • paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.

    • paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.

    •adult  with Ph+ CML in blast crisis.

    • adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.

    • adult patients with relapsed or refractory Ph+ ALL as monotherapy.

    • adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

    • adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.

    The effect of Hronileucem on the outcome of bone marrow transplantation has not been determined.

    Hronileucem is indicated for

    • the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).

    • the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.

    • the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

    In adult and paediatric patients, the effectiveness of Hronileucem is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Hronileucem in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1 of SPC). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

    Subject to medical prescription

    Pharmaceutical form: 100 mg capsules, hard x 120 capsules

    NHIF code: ICD:C18; C19; C20; C92.1

    Pharmaceutical form: 400 mg capsules, hard x 30 capsules

    NHIF code: ICD:C18; C19; C20; C92.1

    АТС: L01XЕ01

    Hronileucem_3d
  • Description

    Ketoprofen is a nonsteroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic activity. It is used for pain relief in some pain syndromes and in the treatment of inflammatory, degenerative and metabolic rheumatic disorders.

    Indications

    Pain:
    - Posoperativе pain;
    - Painful menstruation;
    - pain resulting bone tumor metastasis;
    - Post-traumatic pain.
    Rheumatic diseases:
    - Rheumatoid arthritis;
    - Serologically negative spondylitis (ankylosing spondylitis, psoriatic arthritis, reactive arthritis);
    - Gout, pseudogout;
    - Osteoarthritis;
    - Extraarticular rheumatism (tendonitis, bursitis, capsulitis of the shoulder).

    Subject to medical prescription

    Pharmaceutical form: 100 mg/2 ml solution for injection

    Ketoprofen_3d
  • Description

    ContaMedia Ioh is a contrast agent. It is given before X-ray in order to your doctor can get a clear picture.

    The active substance of ContaMedia Ioh is Iohexol.

    Indications

    ContaMedia Ioh is a X-ray contrast agent for use in adults and children for cardioangiography, arteriography, urography, flebografiya and computer tomography hard image. Lumbar, thoracic and cervical myelography and computed tomography of basal cisterns after subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERP), endoscopic retrograde cholangiopancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract. This medicinal product is for diagnostic purposes only.

    Subject to medical prescription

    Pharmaceutical form: 300 mgI/mL solution for injection x 50ml; 100 ml

    Pharmaceutical form: 350 mgI/mL solution for injection x 50ml; 100 ml

    Contamediaioh 350 ml  3D